NDAORALTABLETPriority Review
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
XPOVIO (selinexor) by Mthera Pharma is nuclear export inhibitors [moa]. Approved for multiple myeloma, endometrial cancer. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XPOVIO (selinexor) is an oral nuclear export inhibitor approved by the FDA on July 3, 2019, developed by Mthera Pharma. It represents a novel mechanism of action targeting XPO1-mediated nuclear export pathways. The drug is currently in its peak lifecycle stage. Specific indications data is not available in the current dataset.
$0.1BPart D
9.3 years to LOEMechanism of Action
Nuclear Export Inhibitors
Pharmacologic Class:
Nuclear Export Inhibitor
Indications (2)
Clinical Trials (20)
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started Jul 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Started May 2026
26 enrolled
MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Started Mar 2026
20 enrolled
Multiple Myeloma
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Started Nov 2025
228 enrolled
Relapsed or Refractory Multiple Myeloma
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
Started Nov 2024
39 enrolled
MDS
Worked on XPOVIO at Mthera Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.